Pfizer Inc. PFE,
And its Germany-based Biotech SE PNTX,
The overall results of the 1/2 phase study of BNT162b2, its COVID-19 vaccine candidate in Germany, were reflected from the US study. The companies said the results support a “positive security profile and strong induction of virus-specific antibody responses.” The 85-day follow-up period showed that the antibody neutralized titers, and that the PND162b2 immunization serra 19 effectively neutralized the pseudo-viruses, indicating that PND162b2 showed protection against the reported mutations. “The results of the ongoing German Phase 1/2 study help explain many of the weapons of the immune system activated by vaccine candidate PND162b2 to fight SARS-CoV-2,” said Katherine Johnson, head of vaccine research and development at Pfizer. . The study concludes that the vaccine is distributed by companies for use in the United Pfizer. It rose 1.5% in market trade and increased its share of Bioendech by 0.9%, the futures ES00,
S&P500 SPX,
Combined with 0.6%.